Literature DB >> 26198874

Expression of circulating microRNAs in patients with ST segment elevation acute myocardial infarction.

Q Ji1, Q Jiang, W Yan, X Li, Y Zhang, P Meng, M Shao, L Chen, H Zhu, N Tian.   

Abstract

AIM: The aim of this study was to investigate microRNA expression in ST segment elevation myocardial infarction (STEMI) and non-ST segment elevation myocardial infarction (NSTEMI), and compare their diagnostic values.
METHODS: We assessed 77 STEMI and 21 NSTEMI patients admitted to the Department of Cardiology in Nanjing First Hospital from October 2013 to August 2014, and 23 healthy volunteers were selected at the same time. Serum miR-133a, miR-133b and miR-499-5p were measured by using quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR), and the concentration of serum cTnI was measured by enzyme-linked immunosorbent assay (ELISA) methods.
RESULTS: The level of miR-133a, miR-133b and miR-499-5p were significantly higher in both STEMI and NSTEMI patients compared to healthy volunteers (P<0.05), and were also considerably increased in the early phase (the first 4 hours) (P<0.05).
CONCLUSION: Serum miR-133a, miR-133b and miR-499-5p can be used as a biomarker for early diagnosis of acute myocardial infarction (AMI).

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26198874

Source DB:  PubMed          Journal:  Minerva Cardioangiol        ISSN: 0026-4725            Impact factor:   1.347


  8 in total

Review 1.  Prospective and therapeutic screening value of non-coding RNA as biomarkers in cardiovascular disease.

Authors:  Albert Busch; Suzanne M Eken; Lars Maegdefessel
Journal:  Ann Transl Med       Date:  2016-06

Review 2.  Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review.

Authors:  Rokas Navickas; Diane Gal; Aleksandras Laucevičius; Agnė Taparauskaitė; Monika Zdanytė; Paul Holvoet
Journal:  Cardiovasc Res       Date:  2016-06-29       Impact factor: 10.787

3.  Circulating miR-320a as a Predictive Biomarker for Left Ventricular Remodelling in STEMI Patients Undergoing Primary Percutaneous Coronary Intervention.

Authors:  Isabel Galeano-Otero; Raquel Del Toro; Agustín Guisado; Ignacio Díaz; Isabel Mayoral-González; Francisco Guerrero-Márquez; Encarnación Gutiérrez-Carretero; Sara Casquero-Domínguez; Luis Díaz-de la Llera; Gonzalo Barón-Esquivias; Manuel Jiménez-Navarro; Tarik Smani; Antonio Ordóñez-Fernández
Journal:  J Clin Med       Date:  2020-04-08       Impact factor: 4.241

4.  Circulating MicroRNA-499 as a Diagnostic Biomarker for Acute Myocardial Infarction: A Meta-analysis.

Authors:  Jingyi Zhao; Hairong Yu; Peng Yan; Xiaohui Zhou; Ying Wang; Yinhui Yao
Journal:  Dis Markers       Date:  2019-05-02       Impact factor: 3.434

5.  Marathon-Induced Cardiac Strain as Model for the Evaluation of Diagnostic microRNAs for Acute Myocardial Infarction.

Authors:  Omid Shirvani Samani; Johannes Scherr; Elham Kayvanpour; Jan Haas; David H Lehmann; Weng-Tein Gi; Karen S Frese; Rouven Nietsch; Tobias Fehlmann; Steffi Sandke; Tanja Weis; Andreas Keller; Hugo A Katus; Martin Halle; Norbert Frey; Benjamin Meder; Farbod Sedaghat-Hamedani
Journal:  J Clin Med       Date:  2021-12-21       Impact factor: 4.241

6.  Evaluating Diagnostic and Prognostic Value of Plasma miRNA133a in Acute Chest Pain Patients Undergoing Coronary Angiography.

Authors:  Jia Ke-Gang; Li Zhi-Wei; Zhang Xin; Wang Jing; Shi Ping; Han Xue-Jing; Tang Hong-Xia; Tang Xin; Liu Xiao-Cheng
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

7.  Structure and functional impact of seed region variant in MIR-499 gene family in bronchial asthma.

Authors:  Eman A Toraih; Mohammad H Hussein; Essam Al Ageeli; Eman Riad; Nouran B AbdAllah; Ghada M Helal; Manal S Fawzy
Journal:  Respir Res       Date:  2017-09-08

8.  The Diagnostic Value of Mir-133a in ST Elevation and Non-ST Elevation Myocardial Infarction: A Meta-Analysis.

Authors:  Yehuda Wexler; Udi Nussinovitch
Journal:  Cells       Date:  2020-03-25       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.